New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 10, 2014
08:25 EDTBSX, BSX, COV, COV, MDT, MDT, STJ, STJLeerink's medical devices analyst holds an analyst/industry conference call
Medical Devices Analyst Antalffy, along with MEDACorp Specialist George Bakris, MD, discusses a SYMPLICITY HTN-3 principal investigator's outlook on the future of the Renal Denervation Market on an Analyst/Industry conference call. Relevant covered companies BSX, COV, MDT and STJ may be discussed on the Analyst/Industry conference call being held on January 10 at 9 am.
News For BSX;COV;MDT;STJ From The Last 14 Days
Check below for free stories on BSX;COV;MDT;STJ the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | all recent news | >>
July 17, 2014
10:00 EDTCOVOn The Fly: Analyst Downgrade Summary
Today's noteworthy downgrades include: 21st Century Fox (FOXA) downgraded to Buy from Strong Buy at ISI Group... Charter (CHTR) downgraded to Hold from Buy at Jefferies... Covidien (COV) downgraded to Hold from Buy at Needham... Diageo (DEO) downgraded to Underweight from Neutral at JPMorgan... GNC Holdings (GNC) downgraded to Hold from Buy at Jefferies... International Game (IGT) downgraded to Market Perform from Outperform at BMO Capital... JAVELIN Mortgage (JMI) downgraded to Market Perform from Outperform at JMP Securities... Macquarie Group (MQBKY) downgraded to Underweight from Neutral at JPMorgan... PNC Financial (PNC) downgraded to Neutral from Buy at Compass Point... PetSmart (PETM) downgraded to Sector Perform from Outperform at RBC Capital... Rexam (REXMY) downgraded to Hold from Buy at Deutsche Bank.
06:41 EDTCOVCovidien downgraded to Hold from Buy at Needham
Subscribe for More Information
July 16, 2014
10:36 EDTCOV, MDTTreasury calls on Congress to halt inversion deals
Subscribe for More Information
08:32 EDTSTJSt. Jude Medical sees revenue growth rate accelerating in 2H
Subscribe for More Information
08:18 EDTSTJ St. Jude Medical sees total Q3 CRM sales $660M-$690M
Sees total FY14 CRM sales $2.81B-$2.85B. Sees Q3 AF product sales $240M-$260M, FY14 AF product sales $1.3B-$1.6B. Sees Q3 cardiovascular product sales $315M-$335M, FY14 cardiovacular product sales $1.36B-$1.39B. Sees Q3 neuromodulation product sales $100M-$110M, sees FY14 neuromodulation product sales $440M-$460M. Sees $15M-$20M related to CardioMEMS product line. Says assumes R&D tax credit will be extended for 2014. Says expects to add $10M-$15M in sales related to NeuroTherm product line in 2014, sees acquisition neutral to EPS in 2014. Sees FY14 gross profit margin 71.5%-72%. Still sees FY14 SG&A as a percentage of net sales to be 33.5%-34%. Sees FY14 effective tax rate 18%-18.5%. Comments made on the Q2 earnings conference call.
07:59 EDTCOV, MDTTreasury Secretary urges Congress to take action on tax inversions
Subscribe for More Information
07:34 EDTSTJSt. Jude Medical raises FY14 adjusted EPS view to $3.96-$4.01 from $3.95-$4.00
Subscribe for More Information
07:32 EDTSTJSt. Jude Medical sees Q3 adjusted EPS 95c-97c, consensus 96c
Subscribe for More Information
07:32 EDTSTJSt. Jude Medical sees FY14 adjusted EPS $3.96-$4.01, consensus $3.99
Sees FY14 revenue $5.64B-$5.76B, consensus $5.7B.
07:31 EDTSTJSt. Jude Medical reports Q2 adjusted EPS $1.02, consensus $1.00
Reports Q2 revenue $1.45B, consensus $1.44B.
07:18 EDTMDTScoliosis Research Society to hold annual meeting
Subscribe for More Information
July 15, 2014
15:19 EDTSTJNotable companies reporting before tomorrow's open
Subscribe for More Information
11:41 EDTSTJSt. Jude Medical technical comments ahead of earnings
Subscribe for More Information
08:00 EDTSTJSt. Jude Medical management to meet with Leerink
Meeting to be held in New York on July 22 hosted by Leerink.
July 14, 2014
19:19 EDTBSXBoston Scientific receives CE Mark for 25 mm Lotus Valve System
Subscribe for More Information
10:00 EDTCOVOn The Fly: Analyst Downgrade Summary
Subscribe for More Information
09:05 EDTSTJSt. Jude Medical to acquire NeuroTerm for approximately $200M in cash
St. Jude Medical has signed a definitive agreement to acquire privately held NeuroTherm, a manufacturer of interventional pain management therapies, for approximately $200M in cash. NeuroTherm is involved in the treatment of spinal pain using radiofrequency ablation, a segment of the chronic pain market in which St. Jude Medical does not currently participate. The company expects to complete this transaction by the end of the third quarter, subject to customary closing conditions. NeuroTherm is expected to add approximately $10M-$15M to St. Jude Medicalís 2014 sales. Excluding acquisition-related expenses, this transaction will be neutral to St. Jude Medicalís consolidated EPS in 2014 and accretive thereafter on a GAAP basis.
09:02 EDTBSXBoston Scientific receives CE mark for Ranger drug-coated balloon
Boston Scientific has received CE Mark for the Ranger Paclitaxel-Coated PTA Balloon Catheter. The technology is now in full European market launch. The Balloon provides physicians with an additional option to treat peripheral artery disease, delivering an anti-stenotic drug to diseased vascular tissue while leaving no permanent implant behind.
07:12 EDTMDT, COVCovidien downgraded to Neutral from Overweight at Piper Jaffray
Subscribe for More Information
06:31 EDTCOVCovidien downgraded to Neutral from Overweight at Piper Jaffray
1 | 2 | 3 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use